Previous Article | Next Article 
Journal of Bacteriology, December 1999, p. 7464-7469, Vol. 181, No. 24
0021-9193/99/$04.00+0
Functional Domains Present in the Mycobacterial
Hemagglutinin, HBHA
Giovanni
Delogu and
Michael J.
Brennan*
Center for Biologics Evaluation and Research,
Food and Drug Administration, Bethesda, Maryland 20892
Received 21 June 1999/Accepted 24 September 1999
 |
ABSTRACT |
Identification and characterization of mycobacterial adhesins and
complementary host receptors required for colonization and dissemination of mycobacteria in host tissues are needed for a more
complete understanding of the pathogenesis of diseases caused by these
bacteria and for the development of effective vaccines. Previous
investigations have demonstrated that a 28-kDa heparin-binding mycobacterial surface protein, HBHA, can agglutinate erythrocytes and
promote mycobacterial aggregation in vitro. In this study, further
molecular and biochemical analysis of HBHA demonstrates that it has
three functional domains: a transmembrane domain of 18 amino acids
residing near the N terminus, a large domain of 81 amino acids
consistent with an
-helical coiled-coil region, and a
Lys-Pro-Ala-rich C-terminal domain that mediates binding to
proteoglycans. Using His-tagged recombinant HBHA proteins and nickel
chromatography we demonstrate that HBHA polypeptides which contain the
coiled-coil region form multimers. This tendency to oligomerize may be
responsible for the induction of mycobacterial aggregation since a
truncated N-terminal HBHA fragment containing the coiled-coil domain
promotes mycobacterial aggregation. Conversely, a truncated C-terminal
HBHA fragment which contains Lys-Pro-Ala-rich repeats binds to the
proteoglycan decorin. These results indicate that HBHA contains at
least three distinct domains which facilitate intercalation into
surface membranes, promote bacterium-bacterium interactions, and
mediate the attachment to sulfated glycoconjugates found in host tissues.
 |
INTRODUCTION |
Mycobacteria are among the most
prominent pathogenic microorganisms, causing disease in both humans and
animals, while tuberculosis is one of the world's leading causes of
death. Although Mycobacterium bovis BCG vaccine is used in
many parts of the world in immunization programs against tuberculosis,
it has met with only limited success (5, 10). It is apparent
that further research on the various steps associated with the
pathogenesis of mycobacterial diseases is needed before the development
of new vaccines or therapeutic approaches against these diseases can be
achieved (6).
One of the initial and crucial events in bacterial pathogenesis is the
adherence of the microorganism to its target tissue. The identification
of adhesins involved in the first steps of colonization may suggest new
approaches to block the infection, either by the development of novel
drugs that interrupt this host-pathogen interaction or through new
vaccine regimens. Mycobacteria have a tropism for the lung, and
interactions of the tubercle bacillus with complement and mannose
receptors on the alveolar macrophages have been implicated in the
uptake of mycobacteria by these phagocytes (32, 33). Since
these microorganisms are easily transmitted by aerosol, the first host
structures they encounter will be those of the respiratory epithelium.
As a result, interactions of the organism with respiratory epithelial
cells or with the extracellular matrix during the initial and
subsequent steps of infection may also be important in pathogenesis.
Recent findings suggest that Mycobacterium tuberculosis may
gain access to the lymphatic and circulatory systems by direct
adherence and penetration of alveolar epithelial cells (23).
Also, infection of pigs with Mycobacterium avium involves
essential interactions with epithelial cells for which the requirement
of specific receptors has been postulated but has yet to be
characterized (4). Finally, binding to host receptors found
on epithelial cells (35) or on interstitial matrix
components may help the dissemination of the microorganism.
Many pathogens, including respiratory pathogens, have been shown to
express a variety of structures on their surfaces which function as
bacterial adhesins (2). Microbial adhesins, such as fimbriae
(18) and the Bordetella pertussis filamentous
hemagglutinin (8, 19, 22), have lectin-like properties, can
agglutinate erythrocytes (RBC), and also bind to complementary
glycoconjugates expressed on the surfaces of host cells. In addition,
adhesins, such as filamentous hemagglutinin (19, 25) and the
Yersinia enterocolitica YadA (1), appear to act
as multifunctional adhesins, capable of mediating bacteria-host cell
interactions, as well as promoting bacterial autoaggregation. Recently,
the putative mycobacterial adhesin HBHA, which has been shown to
agglutinate RBC and aggregate mycobacteria, has been identified
(24, 26). The major goal of the work reported here was, by
using molecular and biochemical strategies, to further characterize
functional sites on the mycobacterial hemagglutinin.
 |
MATERIALS AND METHODS |
All mycobacterial strains used in these studies were from either
the mycobacterial collection of the Laboratory of Mycobacteria, Center
for Biologics Evaluation and Research (CBER), Food and Drug
Administration (FDA), or the Trudeau Institute (Saranac Lake, N.Y.)
mycobacterial collection. The monoclonal antibodies D2 and E4 have been
described previously (30), and the mouse anti-HBHA polyclonal antibody was prepared in the Laboratory of Mycobacteria, CBER, FDA, with a DNA vaccine construct (17).
Purification of native HBHA.
Mycobacteria were grown in 2 liters of Long's synthetic medium (Quality Biological Inc.,
Gaithersburg, Md.) until late log phase. The bacteria were then
pelleted by centrifugation, washed once in Dulbecco's
phosphate-buffered saline (DPBS) containing 0.05% Tween 80 (DPBS/Tw),
resuspended in 100 ml of DPBS/Tw, and heated at 60°C for 30 min. The
bacteria were centrifuged at 20,000 × g for 20 min,
washed with DPBS/Tw, and resuspended in 25 ml of DPBS/Tw containing a 5 mM concentration of protease inhibitor 4-(2-aminomethyl)-benzenesulfonyl fluoride hydrochloride (AEBSF; ICN
Biomedicals Inc., Aurora, Ohio). The mixture was sonicated intermittently for 25 min on ice and then centrifuged at
20,000 × g for 20 min. The sonication and
centrifugation steps were repeated on the cell pellet, and the
supernatants were pooled and centrifuged at 100,000 × g for 1 h. The pellet was discarded, and the final supernatant was resuspended to a final concentration of 2% Triton X-114 for separation of the material into hydrophilic and hydrophobic phases by methods described by Nair et al. (27). The aqueous phase, which contains most of the HBHA protein, was diluted 1:2 in DPBS
and was passed through a heparin-Sepharose CL-6B (Pharmacia/LKB, Piscataway, N.J.) column (1 by 5 cm) equilibrated with DPBS. The column
was then washed with 100 ml of DPBS, and the bound material was eluted
by a 0 to 500 mM NaCl gradient in 100 ml of DPBS. Fractions eluting at
a final NaCl concentration of 300 mM were analyzed by sodium dodecyl
sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) with a 12% gel
followed by Coomassie brilliant blue R-250 staining and Western
blotting with monoclonal antibodies directed against HBHA
(26).
Molecular methods and recombinant protein purification.
The
genes encoding the entire HBHA molecule and the N-terminal fragment
were amplified from M. tuberculosis H37Rv chromosomal DNA
with Vent polymerase (New England BioLabs, Beverly, Mass.) by using the
common primer HB5Nd (5'-AAG CTT ATG GCT GAA AAC TCG AAC ATT-3') found
at the N terminus combined with HB3B (5'-GAA TTC GGA TCC CTA TGC GGT
TTG CAT CCA A-3') for the entire gene and with HB3B1 (5'-GAA TTC GGA
TCC GAA GCT CTG CTG CTG GCT GCG-3') for the N-terminal fragment. The
amplified fragments were cloned in Zero Blunt cloning vector
(Invitrogen, San Diego, Calif.) and then in pET15 (Novagen Inc.,
Madison, Wis.) expression vector by using the NdeI and
BamHI sites. The C-terminal clone for HBHA was derived by
cutting the complete gene with XhoI and BamHI and then inserting it in pET15b. Escherichia coli BL21(DE3)pLysS
was transformed with the three plasmids, and the expressed recombinant histidine-tagged proteins were purified with the X-press system (Invitrogen) under native conditions. The N-terminal recombinant HBHA
fragment (N-h-HBHA) extends from amino acid 1 to 116, and the
C-terminal recombinant HBHA fragment (C-h-HBHA) extends from amino acid
87 to 199.
Nickel chromatography.
To investigate HBHA interactions, we
used a qualitative procedure similar to that described by Rigal et al.
for the TolB proteins of E. coli (29). Purified
recombinant His-tagged HBHA proteins were immobilized on
nickel-chelating resin columns (ProBond; Invitrogen) by methods
suggested by the manufacturer for the X-press system and subsequently
were washed with 200 mM imidazole. Under these conditions most of the
E. coli proteins were washed off the column. Columns were
then washed with phosphate buffer, pH 7.0, containing 150 mM NaCl.
Aliquots (0.3 ml) of the nickel matrix containing similar amounts of
immobilized full-length recombinant HBHA (h-HBHA), N-h-HBHA, and
C-h-HBHA, as determined by SDS-PAGE, were transferred to a
microcentrifuge tube, and identical samples of H37Ra cell lysate or
purified native HBHA were added and mixed gently at 4°C for 1 h,
in a total volume of 0.7 ml. The H37Ra cell lysates used were those
preparations collected after ultracentrifugation as described above for
the purification of native HBHA. All columns were then washed in 8 column volumes of phosphate buffer with increasing concentrations of
50, 100, 200, and 300 mM imidazole, followed by elution with 500 mM
imidazole. Fractions were then concentrated by trichloroacetic acid
precipitation and analyzed for protein content, followed by SDS-PAGE
and Western blotting.
Aggregation assay.
Dispersed M. tuberculosis
H37Ra cells were used in the aggregation test as previously described
(26) to compare the abilities of native and recombinant HBHA
constructs to promote the autoagglutination of the mycobacteria. Native
HBHA was purified on heparin-Sepharose as described above, while
His-tagged recombinant HBHA proteins were purified by Ni column
chromatography, and the His-tagged recombinant protein from E. coli expressing the mycobacterial gene mpt64
(28) was used as a control. Titration experiments were
performed starting at 50 µg per ml, and the results shown are the
averages of three individual experiments.
Binding of HBHA to decorin.
Binding of HBHA to the
proteoglycan decorin (37) (provided by David Mann, Holland
Laboratories, American Red Cross) was assessed by incubating purified
native or recombinant HBHA with 25 µg of decorin per ml immobilized
to plastic in 96-well microtiter plates (Immunolon I; Nunclon). Wells
were incubated with 1% casein for 1 h before adding various
concentrations of purified HBHA diluted in 0.05 M Tris-buffered saline
containing 0.002% Tween 20 (binding buffer). Following a 2-h
incubation at room temperature wells were washed four times with
binding buffer and anti-HBHA mouse serum (1:2,000) was added for 2 h in binding buffer. Wells were washed four times as described above
and incubated with the second antibody (anti-mouse immunoglobulin G;
alkaline phosphatase conjugated; 1:2,000; Sigma, Inc.). Wells were
washed as described above, and, after a 30-min incubation with
phosphatase substrate (pNPP; Kirkegaard & Perry Laboratories,
Gaithersburg, Md.), plates were read for absorbance at 405 nm.
Nonspecific binding was determined by measuring the binding of HBHA to
wells coated with 1% casein. In some experiments, a final
concentration of 0.5 mg of chondroitin sulfate A (Sigma, Inc., St.
Louis, Mo.) per ml was added to HBHA prior to the addition to
decorin-coated wells. Experiments were performed a minimum of two times
with three wells for each data point.
Analytical procedures.
SDS-PAGE was performed as described
originally by Laemmli (16), and immunoblot analyses were
performed by standard procedures as described by Harlow and Lane
(13). Protein concentrations were determined by the method
of Bradford (7) with bovine serum albumin as a standard.
Software analysis.
Computer-assisted analysis available on
the World Wide Web through the Expasy molecular biology server was used
in predicting the secondary structure of the protein. DAS (dense
alignment surface) (11) and TMpred (14) were used
to analyze the transmembrane region of the protein. Coil
(21), Parcoil (3), and Multicoil algorithms were
used to analyze the coiled-coil region.
 |
RESULTS |
Several mycobacterial species express HBHA.
Recently, we have
shown that a mycobacterial protein which agglutinates RBC (HBHA) and
autoagglutinates mycobacteria can be purified from cell extracts and
the growth fluid of M. tuberculosis and M. bovis
BCG strains (24, 26). To determine if other mycobacteria can
express an HBHA-like protein, cell extracts from various mycobacterial species were prepared and chromatographed on heparin-Sepharose. Figure
1 shows fractions from the purification
analyzed by SDS-PAGE and stained with Coomassie blue. The M. tuberculosis and M. bovis strains tested as well as BCG
have a band that migrates at 28 kDa, while HBHA proteins from M. avium, Mycobacterium intracellulare, and
Mycobacterium smegmatis (data not shown) migrate slightly slower on SDS-polyacrylamide gels. All of these heparin-binding protein
bands were recognized by antibodies reactive with the HBHA purified
from M. tuberculosis (data not shown). This suggests that
mycobacteria other than those species belonging to the M. tuberculosis complex can express an HBHA-like protein.

View larger version (58K):
[in this window]
[in a new window]
|
FIG. 1.
Comparison by SDS-PAGE of heparin-binding proteins from
different mycobacterial species stained by Coomassie blue. Lanes: 1, M. avium; 2, M. tuberculosis H37Ra; 3, M. tuberculosis Erdman; 4, M. tuberculosis 956 clinical
isolate; 5, M. bovis BCG; 6, M. bovis.
|
|
Description of functional sites on HBHA.
Comparative sequence
analysis was performed on the HBHA amino acid sequence (24)
to search for potentially important functional sites on the protein. A
comparison of the sequences of HBHA genes obtained from both the
M. tuberculosis H37Rv (Sanger Rv0475) and CDC1551 (Tigre no.
3721) genome banks demonstrates that the amino acid sequences of the
hemagglutinin in both M. tuberculosis strains are identical.
The DAS (dense alignment surface) method (11) and TMpred
(14) were used to predict the presence of a transmembrane region at the N terminus of HBHA (amino acids 12 to 30) (Fig. 2). Analysis of the HBHA amino acid
sequence using algorithms capable of recognizing putative coiled-coil
regions indicates that such a region exists in HBHA. On the basis of
the algorithm of Lupas (21) and the Parcoil and Multicoil
analyses (3), a coiled-coil region in HBHA was predicted to
extend over 81 amino acids (Fig. 3a).
Figure 3b shows amino acid residues in the predicted region aligned as
heptad repeats with the number of predicted
-helical turns occurring
within the coiled-coil region. The particularly strong coiled-coil
potential of amino acids 29 to 65 suggests that this region functions
as a nucleator for a larger sequence, stabilizing the coiled-coil
region perhaps up to amino acid residue 140. It is also likely that the
110 amino acid residues extending between amino acids 29 and 109 (Fig.
2) form a coiled-coil protein that could drive the formation of HBHA
dimers.

View larger version (24K):
[in this window]
[in a new window]
|
FIG. 2.
Schematic showing the putative functional sites found in
intact HBHA and the three His-tagged recombinant HBHA proteins used in
this study. aa, amino acids.
|
|

View larger version (17K):
[in this window]
[in a new window]
|
FIG. 3.
(a) Schematic predicting a coiled-coil region in HBHA
obtained by using the algorithm of Lupas (20, 21). (b)
Predicted heptad repeats found in the coiled-coil domain of HBHA.
Numbers on the left are the amino acid residues. The number of
predicted -helical turns within a given coiled-coil turn (3.6 residues per turn) is shown at the right. Hydrophilic amino acids are
in uppercase, and hydrophobic amino acids are in lowercase.
|
|
Evidence for site-specific HBHA-HBHA interactions.
The
presence of a potential coiled-coil domain in HBHA suggests that
protein-protein interactions between HBHA proteins may occur. To
investigate this, His-tagged recombinant proteins were constructed as
shown in Fig. 2. h-HBHA, N-h-HBHA, and C-h-HBHA were cloned in pET15b,
expressed in E. coli BL21(DE3)pLysS, and purified by nickel
chromatography. We used the avidity of these His-tagged constructs for
nickel (29) and our previous finding that the monoclonal
antibody D2 recognizes native HBHA but not recombinant HBHA (Fig.
4a, lane 1) to investigate HBHA
oligomerization. Previous investigations have suggested that D2
recognizes a specific sugar moiety found on mature native HBHA
(24). An M. tuberculosis H37Ra cell lysate
containing HBHA was incubated with a nickel column containing bound
h-HBHA. The bound material eluted with 500 mM imidazole contained both
native HBHA from the lysate and h-HBHA (Fig. 4a, lane 3), as indicated
by detection with both D2, which recognizes native HBHA only, and E4,
which reacts with both native and recombinant HBHA (24).
Similar results were found when purified native HBHA was added to the
nickel column conjugated with h-HBHA (Fig. 4a, lane 5). For comparison,
lane 2 shows the flowthrough when the H37Ra lysate is chromatographed on nickel only and lane 4 shows the eluted h-HBHA from an h-HBHA nickel
column after the addition of buffer only as a control. Together these
results indicate that HBHA-HBHA interactions can occur.

View larger version (23K):
[in this window]
[in a new window]
|
FIG. 4.
Immunoblots showing HBHA-containing material analyzed by
nickel chromatography and detected by the anti-HBHA monoclonal
antibodies D2 and E4 and by polyclonal HBHA antisera. (a) Lane 1, purified recombinant His-tagged HBHA (h-HBHA); lane 2, flowthrough of
H37Ra extract added to the Ni column only; lane 3, imidazole eluate
from the h-HBHA Ni column after addition of H37Ra extract containing
HBHA; lane 4, imidazole eluate from the h-HBHA Ni column after addition
of buffer only; lane 5, imidazole eluate from the h-HBHA Ni column
after addition of purified native HBHA. (b) Nickel column
chromatography with purified recombinant His-tagged N-terminal
(N-h-HBHA) or C-terminal (C-h-HBHA) fragments of HBHA; detection was
with E4 and anti-HBHA polyclonal (pAb) antisera. Lanes 1 and 3, imidazole eluate following the addition of purified native HBHA to an
N-h-HBHA Ni column; lanes 2 and 4, imidazole eluate following the
addition of native HBHA to a C-h-HBHA Ni column. Arrows show the
positions of the SDS-PAGE molecular mass standards.
|
|
The two recombinant HBHA fragments N-h-HBHA and C-h-HBHA, which migrate
as 14- and 14.5-kDa proteins, respectively, were also
bound to nickel
columns and incubated with the purified native
HBHA (Fig.
4b). When
probed with E4, the imidazole eluate from
the nickel column linked with
N-h-HBHA was found to contain full-length
native HBHA (Fig.
4b, lane
1), but full-length HBHA was not found
in the material eluted from the
nickel column containing the C-terminal
fragment (lane 2). Similar
results were found when an anti-HBHA
polyclonal antiserum which
recognizes the full-length HBHA and
both of the recombinant fragments
was used to detect the eluted
fractions (Fig.
4b, lanes 3 and 4). These
results indicate that
HBHA can form multimers by using interactive
sites found in the
N-terminal fragment of HBHA, a region which contains
the entire
coiled-coil domain of
HBHA.
Aggregation of M. tuberculosis is also promoted by the
N-terminal domain of HBHA.
In an earlier report, we demonstrated
that native purified HBHA promotes the aggregation of mycobacteria, a
process that could be induced by contacts between HBHA molecules on the
surfaces of mycobacteria (26). To determine if the region of
HBHA containing the coiled-coil region can promote bacterial
aggregation, the recombinant HBHA fragments were examined in an
aggregation test using M. tuberculosis H37Ra cells (Table
1). h-HBHA aggregated M. tuberculosis, although more protein was required to produce a
maximum effect compared to purified native HBHA. The N-terminal fragment containing the entire coiled-coil domain of HBHA also aggregated M. tuberculosis, giving maximum aggregation at a
protein concentration of 12.5 µg per ml. No aggregation was observed
with 50 µg of the C-terminal HBHA fragment per ml.
The C-terminal domain of HBHA promotes binding of HBHA to the
proteoglycan decorin.
Previous evidence indicates that a
heparin-binding region of HBHA is found in the C terminus of the
protein (24). Since HBHA binds to heparin, it is likely that
this mycobacterial protein also binds to proteoglycans. To test this
hypothesis, we incubated various concentrations of partially purified
HBHA with a purified preparation of the proteoglycan decorin, which was
immobilized on plastic. Figure 5a shows
that HBHA can bind to decorin (36, 37) in a dose-dependent
fashion and that binding is inhibited in the presence of the
glycosaminoglycan chondroitin sulfate. To localize the binding site on
HBHA, we used the N- and C-terminal His-tagged HBHA recombinant
proteins in the binding assay and found that only the C-terminal HBHA
fragment bound to decorin (Fig. 5b). This extends observations, made
previously (24), that the C-terminal region of HBHA
containing Lys-Pro-Ala-rich repeats was implicated in binding to the
glycosaminoglycan heparin.

View larger version (20K):
[in this window]
[in a new window]
|
FIG. 5.
Binding of native and recombinant HBHA to decorin. (a)
Partially purified HBHA, extracted from M. tuberculosis
H37Ra, from 0 to 5 µg of protein per ml, was incubated with decorin
which had been immobilized on plastic. Bound HBHA (solid squares) was
detected with polyclonal anti-HBHA sera and alkaline
phosphatase-conjugated anti-mouse antibody in an enzyme-linked
immunosorbent assay, as described in Materials and Methods. Open
squares, binding of HBHA to decorin in the presence of 0.5 mg of
chondroitin sulfate A/ml. (b) To measure the binding of recombinant
His-tagged HBHA, purified recombinant HBHA (open bar), C-terminal
recombinant HBHA (hatched bar), and N-terminal recombinant HBHA (solid
bar) were incubated with decorin as described for panel a at a protein
concentration of 5 µg per ml. OD (405 nm), optical density at 405 nm.
|
|
 |
DISCUSSION |
This investigation has provided evidence that the recently
discovered mycobacterial hemagglutinin, HBHA, contains discrete functional domains that may facilitate its function as a bacterial adhesin. All M. tuberculosis and M. bovis
strains, including BCG, that have been tested to date have a 28-kDa
band visualized by SDS-PAGE and reactive with antibodies directed
against HBHA. Other species of mycobacteria including M. avium, M. intracellulare, and M. smegmatis
have a cross-reactive band that migrates at approximately 30 kDa. A
leucine-rich putative transmembrane domain predicted by amino acid
sequencing exists near the N terminus of HBHA (Fig. 2). It is likely
that this domain serves to anchor HBHA in the outer lipid layer on the
mycobacterial surface (9), as previously observed in
immunoelectron microscopy studies (26). HBHA does not
contain the consensus sequence LPXTGX, which has been found to anchor
certain proteins at the surfaces of gram-positive organisms (34).
Lupas (20) and others (38) have shown that a
number of proteins contain coiled-coil domains, a feature that promotes
interactions between homologous as well as heterologous proteins to
form oligomeric structures. In coiled-coil proteins the interactions
among the subunits are mediated by an amino acid sequence that follows
specific rules outlined by Lupas (20). The HBHA sequence
contains a region extending from amino acid 29 to 109 that is a
putative coiled-coil domain as determined by the algorithm of Lupas and
the Berger Parcoil and Multicoil analyses (3, 21). Our
experiments using native HBHA, His-tagged recombinant HBHA proteins,
specific anti-HBHA antibodies, and nickel chromatography provide direct
evidence that HBHA proteins can interact with themselves to form
multimers. Comparative experiments using truncated recombinant HBHA
proteins indicate that multimer formation occurs within the expanse of HBHA containing the coiled-coil domain. Attempts at performing gel
filtration chromatography to estimate the actual size of HBHA have
failed to date, but this may be due to multimerization, the "stickiness" of the protein, or its avidity for plastic surfaces. Therefore, the exact nature of HBHA under physiological conditions remains to be determined.
We have also demonstrated that the recombinant HBHA protein and its
N-terminal fragment containing the coiled-coil domain aggregate
mycobacteria similarly to native HBHA. In contrast, the C-terminal HBHA
fragment containing the heparin-binding domain does not induce
aggregation. This is consistent with the finding that sulfated sugars
do not inhibit HBHA-induced mycobacterial aggregation (8a).
Thus, multimerization of HBHA may, in part, be responsible for the
aggressive interactions between mycobacteria commonly visualized as
"clumping" during in vitro growth. Since it has been shown that
coiled-coil-containing proteins are capable of dynamic switching of
monomer subunits (15), it is possible that HBHA may form
reversible multimeric bridge-like structures connecting bacteria
through the coiled-coil motif. In this model, the addition of purified
HBHA would result in the induction of mycobacterial aggregation in
vitro, as observed in our experiments. HBHA may function like other
prokaryotic proteins, which have been shown to autoagglutinate
bacterial protein, and it has been suggested that these factors are
important for establishing infection and subsequent colonization
(1, 25).
The C-terminal domain of HBHA contains an important site for
interacting with sulfated glycoconjugates, and the avidity of HBHA for
heparin has been used as a tool for purification of the mycobacterial
protein (26). In contrast, HBHA does not bind to proteins
such as bovine serum albumin, ovalbumin, and the extracellular glycoprotein fibronectin (8a). In these studies, we have
demonstrated that HBHA can bind to the proteoglycan decorin, a
macromolecule commonly found in interstitial tissues including the lung
(31, 36, 37). Binding of the C-terminal HBHA recombinant
protein but not the N-terminal fragment and inhibition of binding with chondroitin sulfate suggest that this interaction occurs between the
sulfated glycosaminoglycan extending from the decorin core protein and
the Lys-Pro-Ala repeats found at the C terminus of HBHA. Borrelia
burgdorferi, the causative agent of Lyme disease, has been shown
to express proteins that bind to decorin and mediate adherence of the
organism to host tissues (12), probably by using a similar
Lys-Ala-Pro-rich amino acid motif. In this manner, decorin or other
proteoglycans may serve as receptors for HBHA and mediate attachment of
mycobacteria to host tissues, as has been implied by earlier reports
(24, 26). More-extensive investigations will be required to
determine if there is more avidity of HBHA for certain types of
proteoglycans than for others and to establish its physiological
importance in bacteria-host interactions.
Although the precise function of the mycobacterial hemagglutinin, HBHA,
still needs to be confirmed in vivo, the evidence presented here and in
other reports (24, 26) strongly suggests that the HBHA
molecule is well suited to function as a bacterial adhesin. The
leucine-rich hydrophobic N-terminal domain may anchor HBHA into the
cell walls of mycobacteria. The coiled-coil domain and the
glycosaminoglycan-binding domain of HBHA may then be available to
function at the surface of the bacterium to promote bacteria-bacteria interactions and attachment of the bacteria to host tissues.
 |
ACKNOWLEDGMENTS |
We thank Julie Rouse of CBER, FDA, for technical assistance on
this project. We are also grateful to David Mann of the Holland Laboratories, American Red Cross, for the kind gift of purified decorin
and to Zhongming Li, CBER, FDA, for providing the polyclonal anti-HBHA
antisera. We also thank Alisdair Steven, NIAMS, NIH, for consultation
on the coiled-coil domain of HBHA.
 |
FOOTNOTES |
*
Corresponding author. Mailing address: CBER/FDA, 29 Lincoln Dr. (HFM-431), Bethesda, MD 20892. Phone: (301) 496-9559. Fax: (301) 402-2776. E-mail: Brennan{at}cber.fda.gov.
 |
REFERENCES |
| 1.
|
Balligand, G.,
Y. Laroche, and G. Cornelis.
1985.
Genetic analysis of virulence plasmid from a serogroup 9 Yersinia enterocolitica strain: role of outer membrane protein P1 in resistance to human serum and autoagglutination.
Infect. Immun.
48:782-786[Abstract/Free Full Text].
|
| 2.
|
Beachey, E. H.
1981.
Bacterial adherence: adhesin-receptor interactions mediating the attachment of bacteria to mucosal surface.
J. Infect. Dis.
143:325-345[Medline].
|
| 3.
|
Berger, B.,
D. B. Wilson,
E. Wolf,
T. Tonchev,
M. Milla, and P. S. Kim.
1995.
Predicting coiled coils by use of pairwise residue correlations.
Proc. Natl. Acad. Sci. USA
92:8259-8263[Abstract/Free Full Text].
|
| 4.
|
Bermudez, L. E., and L. S. Young.
1994.
Factors affecting invasion of HT-29 and HEp-2 epithelial cells by organisms of the Mycobacterium avium complex.
Infect. Immun.
62:2021-2026[Abstract/Free Full Text].
|
| 5.
|
Bloom, B. R., and P. E. M. Fine.
1994.
The BCG experience: implications for future vaccines against tuberculosis, p. 531-557.
In
B. R. Bloom (ed.), Tuberculosis: pathogenesis, protection, and control. ASM Press, Washington, D.C.
|
| 6.
|
Bloom, B. R., and C. J. Murray.
1992.
Tuberculosis: commentary on a reemergent killer.
Science
257:1055-1064[Abstract/Free Full Text].
|
| 7.
|
Bradford, M. M.
1976.
A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding.
Anal. Biochem.
72:248-254[Medline].
|
| 8.
|
Brennan, M. J., and R. D. Shahin.
1996.
Pertussis antigens that abrogate bacterial adherence and elicit immunity.
Am. J. Respir. Crit. Care Med.
154:S145-S149.
|
| 8a.
| Brennan, M. J. Unpublished data.
|
| 9.
|
Brennan, P. J., and H. Nikaido.
1995.
The envelope of mycobacteria.
Annu. Rev. Biochem.
64:29-63[Medline].
|
| 10.
|
Colditz, G. A.,
T. F. Brewer,
C. S. Berkey,
M. E. Wilson,
E. Burdick,
H. V. Fineberg, and F. Mosteller.
1994.
Efficacy of BCG vaccine in the prevention of tuberculosis. Meta-analysis of the published literature.
JAMA
271:698-702[Abstract/Free Full Text].
|
| 11.
|
Cserzo, M.,
E. Wallin,
I. Simon,
G. von Heijne, and A. Elofsson.
1997.
Prediction of transmembrane alpha-helices in prokaryotic membrane proteins: the dense alignment surface method.
Protein Eng.
10:673-676[Abstract/Free Full Text].
|
| 12.
|
Guo, B. P.,
S. J. Norris,
L. C. Rosenberg, and M. Hook.
1995.
Adherence of Borrelia burgdorferi to the proteoglycan decorin.
Infect. Immun.
63:3467-3472[Abstract].
|
| 13.
|
Harlow, E., and D. Lane.
1988.
Antibodies, a laboratory manual.
Cold Spring Harbor Laboratory, Cold Spring Harbor, N.Y
|
| 14.
|
Hofmann, K., and W. Stoffel.
1993.
TMbase a database of membrane spanning protein segments.
Biol. Chem. Hoppe-Seyler
347:166.
|
| 15.
|
Hurme, R.,
K. D. Berndt,
S. J. Normark, and M. Rhen.
1997.
A proteinaceous gene regulatory thermometer in Salmonella.
Cell
90:55-64[Medline].
|
| 16.
|
Laemmli, U. K.
1970.
Cleavage of structural proteins during the assembly of the head of bacteriophage T4.
Nature
227:680-685[Medline].
|
| 17.
|
Li, Z.,
A. Howard,
C. Kelley,
G. Delogu,
F. Collins, and S. Morris.
1999.
Immunogenicity of DNA vaccines expressing tuberculosis proteins fused to tissue plasminogen activator signal sequences.
Infect. Immun.
67:4780-4786[Abstract/Free Full Text].
|
| 18.
|
Lindberg, F.,
B. Lund,
L. Johansson, and S. Normark.
1987.
Localization of the receptor-binding protein adhesin at the tip of the bacterial pilus.
Nature
328:84-87[Medline].
|
| 19.
|
Locht, C.,
P. Bertin,
F. D. Menozzi, and G. Renauld.
1993.
The filamentous haemagglutinin, a multifaceted adhesion produced by virulent Bordetella spp.
Mol. Microbiol.
9:653-660[Medline].
|
| 20.
|
Lupas, A.
1996.
Coiled coils: new structures and new functions.
Trends Biochem. Sci.
21:375-382[Medline].
|
| 21.
|
Lupas, A.,
M. Van Dyke, and J. Stock.
1991.
Predicting coiled coils from protein sequences.
Science
252:1162-1164[Free Full Text].
|
| 22.
|
Makhov, A. M.,
J. H. Hannah,
M. J. Brennan,
B. L. Trus,
E. Kocsis,
J. F. Conway,
P. T. Wingfield,
M. N. Simon, and A. C. Steven.
1994.
Filamentous hemagglutinin of Bordetella pertussis. A bacterial adhesin formed as a 50-nm monomeric rigid rod based on a 19-residue repeat motif rich in beta strands and turns.
J. Mol. Biol.
241:110-124[Medline].
|
| 23.
|
McDonough, K. A., and Y. Kress.
1995.
Cytotoxicity for lung epithelial cells is a virulence-associated phenotype of Mycobacterium tuberculosis.
Infect. Immun.
63:4802-4811[Abstract].
|
| 24.
|
Menozzi, F. D.,
R. Bischoff,
E. Fort,
M. J. Brennan, and C. Locht.
1998.
Molecular characterization of the mycobacterial heparin-binding hemagglutinin, a mycobacterial adhesin.
Proc. Natl. Acad. Sci. USA
95:12625-12630[Abstract/Free Full Text].
|
| 25.
|
Menozzi, F. D.,
P. E. Boucher,
G. Riveau,
C. Gantiez, and C. Locht.
1994.
Surface-associated filamentous hemagglutinin induces autoagglutination of Bordetella pertussis.
Infect. Immun.
62:4261-4269[Abstract/Free Full Text].
|
| 26.
|
Menozzi, F. D.,
J. H. Rouse,
M. Alavi,
M. Laude-Sharp,
J. Muller,
R. Bischoff,
M. J. Brennan, and C. Locht.
1996.
Identification of a heparin-binding hemagglutinin present in mycobacteria.
J. Exp. Med.
184:993-1001[Abstract/Free Full Text].
|
| 27.
|
Nair, J.,
D. A. Rouse, and S. L. Morris.
1992.
Nucleotide sequence analysis and serologic characterization of the Mycobacterium intracellulare homologue of the Mycobacterium tuberculosis 19 kDa antigen.
Mol. Microbiol.
6:1431-1439[Medline].
|
| 28.
|
Oettinger, T.,
A. Holm,
I. M. Mtoni,
A. B. Andersen, and K. Hasloov.
1995.
Mapping of the delayed-type hypersensitivity-inducing epitope of secreted protein MPT64 from Mycobacterium tuberculosis.
Infect. Immun.
63:4613-4618[Abstract].
|
| 29.
|
Rigal, A.,
E. Bouveret,
R. Lloubes,
C. Lazdunski, and H. Benedetti.
1997.
The TolB protein interacts with the porins of Escherichia coli.
J. Bacteriol.
179:7274-7279[Abstract/Free Full Text].
|
| 30.
|
Rouse, D. A.,
S. L. Morris,
A. B. Karpas,
J. C. Mackall,
P. G. Probst, and S. D. Chaparas.
1991.
Immunological characterization of recombinant antigens isolated from a Mycobacterium avium gt11 expression library by using monoclonal antibody probes.
Infect. Immun.
59:2595-2600[Abstract/Free Full Text].
|
| 31.
|
Ruoslahti, E.
1989.
Proteoglycans in cell regulation.
J. Biol. Chem.
264:13369-13372[Free Full Text].
|
| 32.
|
Schlesinger, L. S.,
C. G. Bellinger-Kawahara,
N. R. Payne, and M. A. Horwitz.
1990.
Phagocytosis of Mycobacterium tuberculosis is mediated by human monocyte complement receptors and complement component C3.
J. Immunol.
144:2771-2780[Abstract].
|
| 33.
|
Schlesinger, L. S., and M. A. Horwitz.
1990.
Phagocytosis of leprosy bacilli is mediated by complement receptors CR3 and CR3 on human monocytes and complement component C3 in serum.
J. Clin. Investig.
85:1304-1314.
|
| 34.
|
Schneewind, O.,
P. Model, and V. A. Fischetti.
1992.
Sorting of protein A to the staphylococcal cell wall.
Cell
70:267-281[Medline].
|
| 35.
|
Shepard, C.
1957.
Growth characteristics of tubercle bacilli and certain other mycobacteria in HeLa cells.
J. Exp. Med.
105:39-48[Abstract].
|
| 36.
|
Westergren-Thorsson, G.,
J. Hernnas,
B. Sarnstrand,
A. Oldberg,
D. Heinegard, and A. Malmstrom.
1993.
Altered expression of small proteoglycans, collagen, and transforming growth factor-beta 1 in developing bleomycin-induced pulmonary fibrosis in rats.
J. Clin. Investig.
92:632-637.
|
| 37.
|
Yamaguchi, Y.,
D. M. Mann, and E. Ruoslahti.
1990.
Negative regulation of transforming growth factor-beta by the proteoglycan decorin.
Nature
346:281-284[Medline].
|
| 38.
|
Yother, J., and D. E. Briles.
1992.
Structural properties and evolutionary relationships of PspA, a surface protein of Streptococcus pneumoniae, as revealed by sequence analysis.
J. Bacteriol.
174:601-609[Abstract/Free Full Text].
|
Journal of Bacteriology, December 1999, p. 7464-7469, Vol. 181, No. 24
0021-9193/99/$04.00+0
This article has been cited by other articles:
-
Verbelen, C., Dupres, V., Raze, D., Bompard, C., Locht, C., Dufrene, Y. F.
(2008). Interaction of the Mycobacterial Heparin-Binding Hemagglutinin with Actin, as Evidenced by Single-Molecule Force Spectroscopy. J. Bacteriol.
190: 7614-7620
[Abstract]
[Full Text]
-
Esposito, C., Pethoukov, M. V., Svergun, D. I., Ruggiero, A., Pedone, C., Pedone, E., Berisio, R.
(2008). Evidence for an Elongated Dimeric Structure of Heparin-Binding Hemagglutinin from Mycobacterium tuberculosis. J. Bacteriol.
190: 4749-4753
[Abstract]
[Full Text]
-
Verbelen, C., Raze, D., Dewitte, F., Locht, C., Dufrene, Y. F.
(2007). Single-Molecule Force Spectroscopy of Mycobacterial Adhesin-Adhesin Interactions. J. Bacteriol.
189: 8801-8806
[Abstract]
[Full Text]
-
Shin, A-R., Lee, K.-S., Lee, J.-S., Kim, S.-Y., Song, C.-H., Jung, S.-B., Yang, C.-S., Jo, E.-K., Park, J.-K., Paik, T.-H., Kim, H.-J.
(2006). Mycobacterium tuberculosis HBHA Protein Reacts Strongly with the Serum Immunoglobulin M of Tuberculosis Patients.. CVI
13: 869-875
[Abstract]
[Full Text]
-
Delogu, G., Sanguinetti, M., Posteraro, B., Rocca, S., Zanetti, S., Fadda, G.
(2006). The hbhA Gene of Mycobacterium tuberculosis Is Specifically Upregulated in the Lungs but Not in the Spleens of Aerogenically Infected Mice.. Infect. Immun.
74: 3006-3011
[Abstract]
[Full Text]
-
Zanetti, S., Bua, A., Delogu, G., Pusceddu, C., Mura, M., Saba, F., Pirina, P., Garzelli, C., Vertuccio, C., Sechi, L. A., Fadda, G.
(2005). Patients with Pulmonary Tuberculosis Develop a Strong Humoral Response against Methylated Heparin-Binding Hemagglutinin. CVI
12: 1135-1138
[Abstract]
[Full Text]
-
Parra, M., Pickett, T., Delogu, G., Dheenadhayalan, V., Debrie, A.-S., Locht, C., Brennan, M. J.
(2004). The Mycobacterial Heparin-Binding Hemagglutinin Is a Protective Antigen in the Mouse Aerosol Challenge Model of Tuberculosis. Infect. Immun.
72: 6799-6805
[Abstract]
[Full Text]
-
Aoki, K., Matsumoto, S., Hirayama, Y., Wada, T., Ozeki, Y., Niki, M., Domenech, P., Umemori, K., Yamamoto, S., Mineda, A., Matsumoto, M., Kobayashi, K.
(2004). Extracellular Mycobacterial DNA-binding Protein 1 Participates in Mycobacterium-Lung Epithelial Cell Interaction through Hyaluronic Acid. J. Biol. Chem.
279: 39798-39806
[Abstract]
[Full Text]
-
Mueller-Ortiz, S. L., Sepulveda, E., Olsen, M. R., Jagannath, C., Wanger, A. R., Norris, S. J.
(2002). Decreased Infectivity despite Unaltered C3 Binding by a {Delta}hbhA Mutant of Mycobacterium tuberculosis. Infect. Immun.
70: 6751-6760
[Abstract]
[Full Text]
-
Pethe, K., Bifani, P., Drobecq, H., Sergheraert, C., Debrie, A.-S., Locht, C., Menozzi, F. D.
(2002). Mycobacterial heparin-binding hemagglutinin and laminin-binding protein share antigenic methyllysines that confer resistance to proteolysis. Proc. Natl. Acad. Sci. USA
99: 10759-10764
[Abstract]
[Full Text]
-
Brennan, M. J., Delogu, G., Chen, Y., Bardarov, S., Kriakov, J., Alavi, M., Jacobs, W. R. Jr.
(2001). Evidence that Mycobacterial PE_PGRS Proteins Are Cell Surface Constituents That Influence Interactions with Other Cells. Infect. Immun.
69: 7326-7333
[Abstract]
[Full Text]
-
Mueller-Ortiz, S. L., Wanger, A. R., Norris, S. J.
(2001). Mycobacterial Protein HbhA Binds Human Complement Component C3. Infect. Immun.
69: 7501-7511
[Abstract]
[Full Text]
-
Delogu, G., Brennan, M. J.
(2001). Comparative Immune Response to PE and PE_PGRS Antigens of Mycobacterium tuberculosis. Infect. Immun.
69: 5606-5611
[Abstract]
[Full Text]
-
Musser, J. M., Amin, A., Ramaswamy, S.
(2000). Negligible Genetic Diversity of Mycobacterium tuberculosis Host Immune System Protein Targets: Evidence of Limited Selective Pressure. Genetics
155: 7-16
[Abstract]
[Full Text]